Document is current
Any future updates will be listed below
-
Authors
Perez-Correa, Juan-Felipe
Stiehl, Thomas
Marioni, Riccardo E.
Corley, Janie
Cox, Simon R.
Costa, Ivan G.
Wagner, Wolfgang
-
Funding
Funding for this research was provided by:
Wellcome Trust (221890/Z/20/Z)
Deutsche Forschungsgemeinschaft (363055819/GRK2415; WA 1706/12-2 within CRU344/417911533; WA1706/14-1; and particularly by SFB 1506/1)
ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung
Bundesministerium für Bildung und Forschung (VIP + PluripotencyScreen)
Universitätsklinikum RWTH Aachen
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 27 March 2025
First Online: 22 April 2025
Declarations
:
: LBC1936 ethical approval was obtained from the Multicentre Research Ethics Committee for Scotland (baseline, MREC/01/0/56), the Lothian Research Ethics Committee (age 70, LREC/2003/2/29), and the Scotland A Research Ethics Committee (ages 73, 76, 79, 82, 07/MRE00/58). LBC1921 Ethical approval was provided by the Lothian Research Ethics Committee for test waves 1–3 at ages 79, 83, and 87 (LREC/1998/4/183, LREC/2003/7/23, 1702/98/4/183) and the Scotland A Research Ethics Committee for test wave 4 at age 90 (10/MRE00/87, 10/MRE00/87). All participants provided written informed consent.
: Not applicable.
: W.W. is cofounder of Cygenia GmbH that can provide service for various other epigenetic signatures (www.cygenia.com). J-F.P–C. contributes to this company, too. Apart from this, the authors have no competing interests.
